gms | German Medical Science

48th Meeting of the Particle Therapy Co-Operative Group

Particle Therapy Co-Operative Group (PTCOG)

28.09. - 03.10.2009, Heidelberg

Carbon-ion therapy for patients with pancreas cancer

Meeting Abstract

  • S. Yamada - Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan
  • M. Shinoto - Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan
  • H. Imada - Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan
  • S. Yasuda - Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan
  • T. Kamada - Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan
  • H. Tsujii - Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan

PTCOG 48. Meeting of the Particle Therapy Co-Operative Group. Heidelberg, 28.09.-03.10.2009. Düsseldorf: German Medical Science GMS Publishing House; 2009. Doc09ptcog227

DOI: 10.3205/09ptcog227, URN: urn:nbn:de:0183-09ptcog2276

Veröffentlicht: 24. September 2009

© 2009 Yamada et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Carbon ion therapy offers the potential advantages of improved dose localization and enhanced biological effect. We examined the effect of carbon ion therapy in terms of reducing the rate of local recurrence in patients with locally advanced adenocarcinoma of the pancreas or undergoing resection for adenocarcinoma of the pancreas. A Phase I/II Clinical Trial of Carbon-ion Therapy for patients with preoperative pancreas cancer was carried out on surgically resectable patients from June 2000 through February 2003. This was followed by a Phase I/II Clinical Trial of Short-course Carbon-ion Therapy for patients with preoperative pancreas cancer (0203), commencing in April 2003 for similarly surgically resectable patients, with a fractionation regimen from 16 to 8 fractions. In the trial for preoperative therapy (0203) the 5-year overall survival rates were 30% for all patients and 51% in the resected patients, respectively, The reported 5-year overall survival rate in patients with pancreas cancer treated by curative surgery were 15-25%. Concurrently, a Phase I/II Clinical Trial of Carbon-ion Therapy for patients with locally advanced pancreas cancer was conducted for surgically non-resectable patients with local progressive disease without distant metastasis from April 2003 through February 2007(0204). The local control rate at one year in the 46 analyzed patients and in the patients receiving 45.6GyE or more were 76% and 95% respectively. The one year overall survival rate were 44% at all patients, and 40% at lower than 43.2GyE and 73% at higher than 45.6GyE respectively. From the results of the 0204 clinical study, carbon ion radiotherapy considerably improved tumor control of locally advanced pancreas cancer with acceptable morbidity in the surrounding normal tissues, but sufficient survival benefit could not be achieved. We started a Phase I/II Clinical Trial of Gemcitabine Combined with Carbon-ion Therapy for patients with locally advanced pancreas cancer. This trial is still ongoing. Gemcitabine combined with carbon ion radiotherapy may be well tolerated by patients with pancreas cancer.